Study Explains Why Obesity Drugs Work Differently for Women and Men
With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio Labs has released a groundbreaking study. The data uncover fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic? and Zepbound®. Olio Labs‘ study uncovers unprecedented insights into GLP-1 drug effectiveness across sexes, addressing a critical research gap in a market where women make up 70% of patients. To learn more, read the paper On the Sex Differences in GLP-1 Signaling Across Species
